Every 10-Q that Vericel (VCEL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCEL filings page.
Vericel Corporation reported improved financial performance for the quarter ended June 30, 2026. Total revenue was 77,457 (amounts in thousands), up 22.5% year over year, driven mainly by MACI at 65,506, Epicel at 10,404 and NexoBrid at 1,547. Gross profit reached 56,402 and income from operations was 434, producing net income of 2,206, or $0.04 per diluted share, versus a net loss of 553 a year earlier.
For the first six months of 2026, revenue was 145,882 (amounts in thousands) and the net loss narrowed to 4,096 from 11,799. As of June 30, 2026, cash and cash equivalents were $125.4 million and investments were $102.1 million. Operating activities provided 32,574 (amounts in thousands) of cash, and there were no borrowings under the $150.0 million revolving credit facility. The company expects existing cash, investments and borrowing capacity to fund operations for at least 12 months.
Strategically, Vericel continued ramping MACI manufacturing at its Burlington facility and advanced MACI Arthro and the MASCOT ankle study. It entered a BARDA agreement valued at up to $196.9 million for NexoBrid procurement and development, and in July 2026 authorized a $200.0 million open-ended share repurchase program.
Vericel Corporation reported first-quarter 2026 results with total revenue of $68.4 million, up 30% from $52.6 million a year earlier, driven by strong growth in MACI and Epicel. Net loss narrowed to $6.3 million, or $0.12 per share, from $11.2 million.
MACI revenue rose to $56.4 million and Epicel to $10.9 million, while NexoBrid contributed $1.1 million. Vericel ended the quarter with $109.3 million in cash and cash equivalents and $101.3 million in investments, and had no borrowings under its $150 million revolving credit facility.
The company also entered a ten-year agreement with BARDA valued at up to $196.9 million to procure NexoBrid, build vendor-managed inventory, and fund development work, including a potential blast trauma indication and U.S.-based manufacturing capabilities.
Vericel (VCEL) filed its Q3 2025 Form 10‑Q, reporting total revenue of $67.503 million, up 16.6% year over year, and net income of $5.074 million versus a loss in the prior year period. Gross profit was $49.585 million as MACI led growth.
Product mix shifted: MACI revenue rose to $55.662 million (up 24.6%), NexoBrid increased to $1.466 million, while Epicel declined to $10.375 million. For the nine months, revenue reached $183.341 million (up 13.3%) with a narrower net loss of $6.725 million.
Balance sheet and liquidity: Cash and cash equivalents were $100.403 million, with investments of $84.641 million. The company has a $150.0 million undrawn revolving credit facility and total shareholders’ equity of $321.858 million. Operating lease liabilities totaled $98.006 million current and long‑term combined.
Operational updates: MACI Arthro remained in market following the 2024 sBLA approval enabling arthroscopic delivery. Management highlighted Burlington, MA facility progress and continued U.S. commercialization of NexoBrid under the MediWound supply agreements.